Facts
- Product: Recombinant fibrinogeen
- Sector: Life Sciences & Health
- Founded: 2014
- Amount invested: € 300,000
- Status: Follow-up financing secured
Healing wounds with fibrinogen
Fibriant was founded by former ProFibrix CEO Jaap Koopman (CEO), Miranda Weggeman (CTO) and Jos Grimbergen (COO). The company focuses on developing and producing recombinant fibrinogen. A protein that is present in the blood, fibrinogen plays an important role in blood clotting, tissue repair and the body’s natural defence against infections. When bleeding occurs, fibrinogen is converted to fibrin, which forms strands where the blood vessel is damaged. The blood platelets bind with the network of fibrin strands, allowing the wound to close.